Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$96.65 ▲ +0.68
(+0.71%)
MKT CAP: $6.40B • VOL: 657.3K
52W L $25 52W H $116
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$81
MEDIAN
$108
MEAN
$110
HIGH
$131
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ORKA TAPE
ORKA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $116.95 | $111.15 | 2025-02-14 | $87.95 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $121.78 | $114.05 | 2025-02-06 | $90.85 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $110.18 | $106.32 | 2025-01-29 | $92.78 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $98.58 | — | 2025-01-17 | $94.72 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $85.05 | $91.82 | 2025-01-09 | $86.02 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $115.01 | $100.52 | 2024-12-18 | $84.09 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $93.75 | $97.62 | 2024-12-04 | $89.88 | -4.3% | 48% | C |